Hinge Health, Inc. (HNGE) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Hinge Health, Inc. stock (HNGE) is currently trading at $40.19. Hinge Health, Inc. PS ratio (Price-to-Sales) is 5.48. Analyst consensus price target for HNGE is $58.25. WallStSmart rates HNGE as Sell.
- HNGE PE ratio analysis and historical PE chart
- HNGE PS ratio (Price-to-Sales) history and trend
- HNGE intrinsic value — DCF, Graham Number, EPV models
- HNGE stock price prediction 2025 2026 2027 2028 2029 2030
- HNGE fair value vs current price
- HNGE insider transactions and insider buying
- Is HNGE undervalued or overvalued?
- Hinge Health, Inc. financial analysis — revenue, earnings, cash flow
- HNGE Piotroski F-Score and Altman Z-Score
- HNGE analyst price target and Smart Rating
Hinge Health, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Hinge Health, Inc. (HNGE) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around return on equity and price/book. Mixed signals suggest waiting for clearer direction before acting.
Hinge Health, Inc. (HNGE) Key Strengths (3)
Revenue surging 45.60% year-over-year
97.58% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Hinge Health, Inc. (HNGE) Areas to Watch (6)
Company is destroying shareholder value
Earnings declining -80.80%, profits shrinking
Company is losing money with a negative profit margin
Very expensive at 18.7x book value
Premium valuation at 5.5x annual revenue
Decent operational efficiency, solid but not exceptional
Supporting Valuation Data
Hinge Health, Inc. (HNGE) Detailed Analysis Report
Overall Assessment
This company scores 36/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 3 register as strengths (avg 9.0/10) while 6 fall into concern territory (avg 2.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own., Market Cap. Growth metrics are encouraging with Revenue Growth at 45.60%.
The Bear Case
The primary concerns are Return on Equity, EPS Growth, Profit Margin. Some valuation metrics including Price/Sales (5.48), Price/Book (18.73) suggest expensive pricing. Growth concerns include EPS Growth at -80.80%, which may limit upside. Profitability pressure is visible in Return on Equity at -132.90%, Operating Margin at 16.00%, Profit Margin at -89.90%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -132.90% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 45.60% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and EPS Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
HNGE Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
HNGE's Price-to-Sales ratio of 5.48x sits near its historical average of 4.8x (59th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 11% below its historical high of 6.16x set in Mar 2026, and 144% above its historical low of 2.25x in Jan 2026. Over the past 12 months, the PS ratio has expanded from ~3.8x, reflecting growing market expectations outpacing revenue growth.
Compare HNGE with Competitors
Top HEALTH INFORMATION SERVICES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Hinge Health, Inc. (HNGE) · HEALTHCARE › HEALTH INFORMATION SERVICES
The Big Picture
Hinge Health, Inc. is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 588M with 46% growth year-over-year. The company is currently unprofitable, posting a -89.9% profit margin.
Key Findings
Revenue growing at 46% YoY, reaching 588M. This pace significantly outperforms most HEALTH INFORMATION SERVICES peers.
Generating 63M in free cash flow and 64M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -89.9% profit margin. The path to breakeven will be the key catalyst.
Earnings fell 81% YoY while revenue grew 46%. This gap usually reflects one-time items (tax benefits, write-offs) in the prior period, not an operational decline.
What to Watch Next
Growth sustainability: can Hinge Health, Inc. maintain 46%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor HEALTH INFORMATION SERVICES industry trends, competitive moves, and regulatory changes that could impact Hinge Health, Inc..
Bottom Line
Hinge Health, Inc. is a high-conviction growth story with revenue accelerating at 46% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -89.9% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 10:11:34 AM
About Hinge Health, Inc.(HNGE)
NYSE
HEALTHCARE
HEALTH INFORMATION SERVICES
USA
Hinge Health, Inc. develops health care software for joint and muscle health. The company is headquartered in San Francisco, California.